Retatrutide Phase 3 Clinical Trial Results: The Benefits Beyond Weight Loss

Most coverage of retatrutide stops at the headline weight-loss number — approximately 28 to 30 percent of body weight in phase 3 trials, the largest ever documented for a pharmaceutical compound. That is the wrong place to stop reading. Phase 3 data document sweeping improvements across glucose regulation, liver fat, cardiovascular risk markers, joint pain, sleep apnea, and energy expenditure. Here is the full picture.

Back to Blog